{ "schemaVersion": 2, "eyebrow": "Dermatology", "title": "Onychomycosis", "summary": "Confirm fungal infection before committing patients to prolonged therapy, obtain an adequately proximal subungual specimen, and select topical versus oral treatment by extent, organism, contraindications, interactions, and treatment goals.", "seoDescription": "Physician guide to confirming onychomycosis, optimizing nail sampling, selecting topical or oral therapy, and monitoring terbinafine safely.", "clinicalQuestion": "How should clinicians confirm, treat, and monitor suspected onychomycosis while avoiding inappropriate systemic antifungal exposure?", "specialty": "Dermatology", "audience": "U.S. physicians and medical trainees", "tags": [ "onychomycosis", "tinea unguium", "terbinafine", "nail PAS", "fungal culture", "KOH preparation", "efinaconazole" ], "keyTakeaways": [ "Before prolonged antifungal treatment, obtain mycologic confirmation because traumatic onycholysis, psoriasis, lichen planus, and trachyonychia can mimic onychomycosis. [8][21]", "For distal-lateral disease, sample the most proximal affected subungual material rather than distal detached plate; viable fungi are concentrated near the proximal edge of nail-plate attachment. [10][24]", "Nail clipping histology with PAS is the most sensitive commonly used single test; culture has lower sensitivity but can identify the causative organism. [7][9][12]", "For dermatophyte onychomycosis requiring systemic treatment, oral terbinafine 250 mg daily for 6 weeks for fingernails or 12 weeks for toenails is FDA-labeled; chronic or active liver disease is a contraindication. [1]", "Use topical treatment when disease is limited or oral therapy is unsuitable; expect a longer course and lower effectiveness than systemic therapy. [20][22][24]", "Review CYP2D6-mediated interaction risk before terbinafine, particularly with tricyclic antidepressants, SSRIs, atypical antipsychotics, beta blockers, and tamoxifen. [21][23]" ], "sections": [ { "id": "confirm-before-treatment", "eyebrow": "Diagnostic decision", "heading": "Confirm fungus before selecting treatment", "intro": "Clinical appearance directs sampling but does not establish the diagnosis.", "paragraphs": [ "Test clinically suspected onychomycosis before committing a patient to prolonged treatment, particularly before an oral agent. Nail dystrophy from traumatic onycholysis, psoriasis, lichen planus, trachyonychia, and toe or foot deformity can resemble distal-lateral subungual disease; an incorrect diagnosis exposes patients to unnecessary systemic adverse effects and delays diagnosis of another nail disorder. [8][21]", "Use direct KOH microscopy as a rapid first test when an immediate result will change the visit plan. If KOH is negative but clinical suspicion remains high, submit a nail clipping for PAS histology and/or fungal culture rather than treating the negative test as exclusionary; reported KOH sensitivity is variable, and PAS generally outperforms KOH and culture for detecting fungal elements. [18][21]", "Add fungal culture when organism identification will alter management, including suspected yeast or nondermatophyte mold infection, atypical morphology, prior treatment failure, or anticipated alternative systemic therapy. A positive PAS confirms fungal invasion but does not identify species; culture provides organism identification but has lower positivity and is slow. [3][7][12]" ], "bullets": [ "Use dermoscopy as an adjunct to select a representative nail and strengthen the differential while awaiting mycologic testing; it does not replace KOH, PAS, culture, or molecular testing. [11][18]", "In distal-lateral subungual onychomycosis, debride detached distal nail and collect subungual debris from the most proximal involved area. Distal plate sampling reduces culture yield. [10][24]", "If KOH is positive, proceed with treatment selection; if KOH is negative and PAS is positive, fungal infection is established but species is not. [7][9][12]" ], "subsections": [], "table": { "caption": "Common diagnostic options and the management question each answers. [7][9][12][21]", "columns": [ "Test", "Result timing and diagnostic role", "Key limitation", "When it changes management" ], "rows": [ [ "KOH preparation", "Minutes; rapid detection of fungal elements. [12][21]", "Sensitivity is variable and a negative result does not reliably exclude infection. [18]", "A positive result supports treatment at the initial visit; a negative result with persistent suspicion should prompt PAS and/or culture. [21]" ], [ "Nail clipping with PAS histology", "Days; highest reported positivity among common outpatient tests and highly sensitive for fungal elements. [7][9][12]", "Does not identify fungal species and requires pathology processing. [12]", "Useful after negative KOH with persistent suspicion or before systemic therapy when diagnostic certainty is needed. [21]" ], [ "Fungal culture", "Weeks; identifies viable organism and can distinguish dermatophytes from other fungi. [3][13]", "Lower sensitivity than KOH and PAS; false-negative results occur with inadequate or distal sampling. [7][10]", "Use when species identification is likely to affect drug choice or when disease is atypical or refractory. [3]" ] ] } }, { "id": "choose-treatment-by-burden", "eyebrow": "Treatment selection", "heading": "Choose topical versus systemic therapy by extent and constraints", "intro": "Treatment is elective for some patients and should be tied to expected benefit.", "paragraphs": [ "Offer treatment when nail disease causes pain, functional limitation, distress, or creates clinically important risk, including a history of lower-extremity cellulitis or diabetes with additional cellulitis risks such as prior cellulitis, venous insufficiency, or edema. Treatment is not mandatory for every confirmed infection; align the regimen with nail burden, patient preference, interaction risk, and ability to adhere to a prolonged course. [21][24]", "Use an oral agent when disease is moderate to severe, involves multiple nails, or when the likelihood of topical penetration is poor. Expert guidance summarized in a clinical review reserves systemic agents for moderate involvement of 20% to 60% of the nail plate and severe involvement above 60%; topical therapy is an option for mild-to-moderate disease at 60% or less or when oral therapy is contraindicated. [24]", "For confirmed dermatophyte disease requiring systemic treatment, prescribe terbinafine 250 mg orally once daily for 6 weeks for fingernail onychomycosis or 12 weeks for toenail onychomycosis. Terbinafine is FDA-indicated for dermatophyte onychomycosis and is generally preferred to topical therapy because it is more effective and has a shorter treatment duration. [1][21]", "Use topical therapy when infection is limited, systemic drug interactions or hepatic disease preclude terbinafine, or the patient prioritizes avoidance of systemic toxicity. Efinaconazole 10% solution and tavaborole 5% solution are FDA-approved for toenail onychomycosis; ciclopirox 8% lacquer is FDA-approved for fingernail and toenail disease. Topical treatment has negligible systemic interaction risk but requires longer treatment and has limited cure rates relative to oral therapy. [22][24]" ], "bullets": [ "For ciclopirox lacquer, treatment typically lasts 48 weeks and includes weekly removal of residual lacquer, weekly patient debridement, and monthly professional debridement. [24]", "Do not routinely start oral-plus-topical combination therapy initially; systematic-review authors recommend reserving combination treatment for second-line use because the incremental evidence is limited and study methods are heterogeneous. [22]", "Discuss realistic outcomes: reported complete cure rates range from 35% to 55% for terbinafine, 14% to 43% for itraconazole, and 21% to 48% for fluconazole; visible nail normalization lags behind microbiologic clearance. [20]" ], "subsections": [ { "heading": "When terbinafine is unsuitable", "paragraphs": [ "Do not prescribe oral terbinafine to patients with chronic or active liver disease. Evaluate for liver disease before treatment; liver failure requiring transplant or resulting in death has occurred. [1]", "If an oral alternative is needed because terbinafine is contraindicated, poorly tolerated, or poses a consequential interaction, itraconazole is FDA-approved and has activity against dermatophytes, yeasts, and nondermatophyte molds. Reported regimens include 200 mg daily for 3 months or 400 mg daily for 1 week followed by 3 weeks off treatment for four pulses. [20]", "Fluconazole is commonly used off-label for onychomycosis; reserve its consideration for situations in which an off-label alternative is appropriate after organism, interaction, and patient-specific risk review. [20]" ], "bullets": [] } ], "table": { "caption": "Treatment selection for confirmed onychomycosis. [1][20][22][24]", "columns": [ "Clinical situation", "Preferred approach", "Regimen or practical implication", "Important tradeoff" ], "rows": [ [ "Confirmed dermatophyte infection requiring systemic therapy", "Oral terbinafine. [1][21]", "250 mg orally once daily for 6 weeks for fingernails or 12 weeks for toenails. [1]", "Avoid in chronic or active liver disease; review CYP2D6 interaction risk. [1][23]" ], [ "Mild-to-moderate involvement at 60% or less, or oral therapy unsuitable", "Topical antifungal. [24]", "Efinaconazole 10% or tavaborole 5% for toenails; ciclopirox 8% for finger- or toenails. [22]", "Long treatment duration and lower effectiveness than oral therapy. [20][24]" ], [ "Suspected yeast or nondermatophyte mold, atypical disease, or treatment failure", "Obtain culture before changing systemic therapy. [3][12]", "Consider itraconazole after organism-directed review; reported regimens are 200 mg daily for 3 months or pulse therapy. [20]", "Culture may be falsely negative; ensure proximal subungual sampling. [10]" ], [ "Failure of an appropriately selected initial regimen", "Reconfirm diagnosis and reassess specimen quality, organism, adherence, and competing nail disease. [8][10][22]", "Reserve oral-plus-topical combination treatment for second-line use. [22]", "Recurrence and relapse remain common despite treatment. [20]" ] ] } }, { "id": "terbinafine-safety", "eyebrow": "Prescribing safety", "heading": "Screen and counsel before oral terbinafine", "intro": "The pre-prescription review should determine whether terbinafine is safe and whether another agent is needed.", "paragraphs": [ "Before terbinafine, evaluate for chronic or active liver disease and review the medication list for CYP2D6-sensitive drugs. Terbinafine inhibits CYP2D6; clinically relevant interaction review is particularly important for tricyclic antidepressants, SSRIs, atypical antipsychotics, beta blockers, tamoxifen, and metoprolol. [1][20][21][23]", "Counsel patients to report symptoms compatible with drug reaction, depressive symptoms, or clinically significant adverse effects. The FDA label reports headache, diarrhea, rash, dyspepsia, liver-enzyme abnormalities, pruritus, taste disturbance, nausea, abdominal pain, and flatulence among common adverse reactions; discontinue terbinafine if signs or symptoms of drug reaction occur. [1]", "Set expectations before starting therapy: complete cure requires both mycologic clearance and a visually clear nail, and reported cure rates are limited even with oral therapy. Relapse has been reported as high as 25%, and recurrence estimates range from 6.5% to 53%; reassess persistent dystrophy with repeat mycologic testing rather than reflexively extending or repeating systemic therapy. [20]" ], "bullets": [ "Terbinafine 250 mg tablets may be taken without regard to food. [23]", "For a patient taking metoprolol or another consequential CYP2D6 substrate, avoid assuming that terbinafine is the default oral option; consider an organism-informed alternative or topical treatment. [20][23]", "A normal-appearing nail is not an appropriate early endpoint during treatment because nail growth is required for visible replacement of diseased plate. Complete cure should not be judged solely during the medication course. [20]" ], "subsections": [], "table": { "caption": "Terbinafine pre-treatment and follow-up decisions. [1][20][21][23]", "columns": [ "Decision point", "Action", "Interpretation or next step" ], "rows": [ [ "Before prescribing", "Evaluate for chronic or active liver disease. [1]", "Chronic or active liver disease is a contraindication to oral terbinafine. [1]" ], [ "Medication reconciliation", "Review CYP2D6 substrates and psychotropic, beta-blocker, and tamoxifen exposure. [21][23]", "If interaction risk is consequential, choose a different strategy rather than automatically prescribing terbinafine. [20]" ], [ "During treatment", "Ask about rash, taste disturbance, gastrointestinal effects, mood symptoms, and symptoms of drug reaction. [1]", "Discontinue terbinafine if signs or symptoms of drug reaction occur. [1]" ], [ "Persistent or recurrent dystrophy", "Repeat mycologic assessment and reconsider alternative diagnoses, sampling quality, and organism. [8][10][20]", "Do not equate residual abnormal appearance with proven active dermatophyte infection. [20]" ] ] } }, { "id": "failure-and-recurrence", "eyebrow": "Escalation", "heading": "Approach apparent treatment failure systematically", "intro": "Failure should trigger diagnostic reassessment before drug escalation.", "paragraphs": [ "When a nail remains abnormal after an adequate course, first distinguish slow outgrowth from active infection. Because complete cure requires mycologic and clinical clearance and relapse or recurrence is common, obtain repeat KOH, PAS, and/or culture from a properly collected proximal subungual specimen before repeating systemic treatment. [10][20]", "A negative culture alone does not reliably exclude persistent infection because culture is less sensitive than PAS and is vulnerable to poor sampling. If repeated testing does not confirm fungus, redirect the workup toward mimics such as traumatic onycholysis, psoriasis, lichen planus, or trachyonychia rather than exposing the patient to serial antifungal courses. [7][8][9][12]", "If culture identifies a nondermatophyte mold or yeast, or if disease is atypical or recalcitrant, use the identified organism to reassess drug selection. Itraconazole has broader reported activity against dermatophytes, yeasts, and nondermatophyte molds, whereas terbinafine is FDA-indicated specifically for dermatophyte onychomycosis. [1][20]" ], "bullets": [ "Reassess adherence before labeling topical treatment ineffective; topical regimens are prolonged and adherence is a recognized limitation. [24]", "Consider second-line combination therapy only after confirmation of ongoing infection and review of initial-treatment adequacy. [22]", "Do not rely on dermoscopy alone to document persistence or cure; it is an adjunct, not a substitute for mycologic testing. [11]" ], "subsections": [], "table": { "caption": "Next steps after inadequate response. [7][8][10][20][22]", "columns": [ "Observed problem", "Most useful next action", "Why it matters" ], "rows": [ [ "Persistent dystrophic nail after therapy", "Repeat mycologic testing using proximal subungual material. [10][20]", "Separates residual nail damage or delayed outgrowth from persistent infection. [20]" ], [ "Negative culture but high clinical suspicion", "Obtain PAS histology and reassess collection site. [7][9][10]", "PAS is more sensitive than culture, and distal sampling lowers culture sensitivity. [7][10]" ], [ "Repeated negative fungal studies", "Evaluate for traumatic, inflammatory, and other nonfungal nail disorders. [8]", "Avoids repeated unnecessary antifungal exposure. [8]" ], [ "Confirmed infection after appropriate monotherapy", "Review organism, adherence, drug interactions, and second-line combination options. [20][22]", "Combination therapy should not be routine first-line management. [22]" ] ] } } ], "faq": [], "references": [ { "number": 1, "title": "These highlights do not include all the information needed to use TERBINAFINE TABLETS safely and effectively. See full prescribing information for TERBINAFINE TABLETS.\n \n \n TERBINAFINE tablets, for oral use\n \n \n Initial U.S. Approval: 1992", "detail": "dailymed.nlm.nih.gov", "url": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=34221c17-0d8c-4b56-8af3-c74efab4599e&%3Btype=display", "authors": "dailymed.nlm.nih.gov", "host": "dailymed.nlm.nih.gov" }, { "number": 2, "title": "Cost-effectiveness of Confirmatory Testing Before ...", "detail": "jamanetwork.com", "url": "https://jamanetwork.com/journals/DERM/articlepdf/2475012/doi150055.pdf", "authors": "jamanetwork.com", "host": "jamanetwork.com" }, { "number": 3, "title": "S1 Guideline onychomycosis - Nenoff - 2023 - Wiley Online Library", "detail": "onlinelibrary.wiley.com", "url": "https://onlinelibrary.wiley.com/doi/10.1111/ddg.14988", "authors": "onlinelibrary.wiley.com", "host": "onlinelibrary.wiley.com" }, { "number": 4, "title": "British Association of Dermatologists' guidelines for the ...", "detail": "onlinelibrary.wiley.com", "url": "https://onlinelibrary.wiley.com/doi/10.1111/bjd.13358", "authors": "onlinelibrary.wiley.com", "host": "onlinelibrary.wiley.com" }, { "number": 5, "title": "Onychomycosis: a review - Gupta - 2020 - Wiley Online Library", "detail": "onlinelibrary.wiley.com", "url": "https://onlinelibrary.wiley.com/doi/abs/10.1111/jdv.16394", "authors": "onlinelibrary.wiley.com", "host": "onlinelibrary.wiley.com" }, { "number": 6, "title": "What can GP data tell us about the treatment of onychomycosis in ...", "detail": "onlinelibrary.wiley.com", "url": "https://onlinelibrary.wiley.com/doi/full/10.1002/ski2.84", "authors": "onlinelibrary.wiley.com", "host": "onlinelibrary.wiley.com" }, { "number": 7, "title": "Comparison of diagnostic methods in the evaluation of onychomycosis - ScienceDirect", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/science/article/pii/S0190962203014804", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com" }, { "number": 8, "title": "Accuracy of Dermoscopy as a Point-of-Care Tool... : Journal of the Philippine Dermatological Society", "detail": "journals.lww.com", "url": "https://journals.lww.com/jpds/_layouts/15/oaks.journals/downloadpdf.aspx?an=01671546-202511000-00002", "authors": "journals.lww.com", "host": "journals.lww.com" }, { "number": 9, "title": "Comparative Evaluation of Potassium Hydroxide Mount, Fungal ... : Indian Journal of Dermatopathology and Diagnostic Dermatology", "detail": "journals.lww.com", "url": "https://journals.lww.com/ijdd/fulltext/2021/08010/comparative_evaluation_of_potassium_hydroxide.2.aspx", "authors": "journals.lww.com", "host": "journals.lww.com" }, { "number": 10, "title": "Onychomycosis: An evaluation of three sampling methods - ScienceDirect", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/science/article/pii/S0190962298702816", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com" }, { "number": 11, "title": "Dermoscopy of Onychomycosis for the Podiatrist - ScienceDirect", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/science/article/pii/S089184222100046X", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com" }, { "number": 12, "title": "Methods for Diagnosing Onychomycosis: A Comparative Study... : Dermatologica Sinica", "detail": "journals.lww.com", "url": "https://journals.lww.com/ders/fulltext/2019/37020/methods_for_diagnosing_onychomycosis__a.1.aspx", "authors": "journals.lww.com", "host": "journals.lww.com" }, { "number": 13, "title": "Diagnosis of onychomycosis made simple - ScienceDirect", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/science/article/abs/pii/S0190962299703919", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com" }, { "number": 14, "title": "[PDF] Topical Antifungal Prescribing for Medicare Part D Beneficiaries - CDC", "detail": "www.cdc.gov", "url": "https://www.cdc.gov/mmwr/volumes/73/wr/pdfs/mm7301-H.pdf", "authors": "www.cdc.gov", "host": "www.cdc.gov" }, { "number": 15, "title": "Traitements topiques et à l'aide de dispositifs pour les ...", "detail": "www.cochranelibrary.com", "url": "https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012093.pub2/references/fr", "authors": "www.cochranelibrary.com", "host": "www.cochranelibrary.com" }, { "number": 16, "title": "[PDF] List of Publications Using Data from NAMCS and NHAMCS - CDC", "detail": "www.cdc.gov", "url": "https://www.cdc.gov/nchs/media/pdfs/2024/08/namcs_nhamcs_publication_list.pdf", "authors": "www.cdc.gov", "host": "www.cdc.gov" }, { "number": 17, "title": "Vital and Health Statistics; Series 11, No. 212 (11/78)", "detail": "www.cdc.gov", "url": "https://www.cdc.gov/nchs/data/series/sr_11/sr11_212.pdf", "authors": "www.cdc.gov", "host": "www.cdc.gov" }, { "number": 18, "title": "Diagnosing Onychomycosis: What’s New? - PMC", "detail": "www.ncbi.nlm.nih.gov", "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9146047", "authors": "www.ncbi.nlm.nih.gov", "host": "www.ncbi.nlm.nih.gov" }, { "number": 19, "title": "[PDF] Confocal Microscopy in Clinical and Surgical Dermatology", "detail": "stacks.cdc.gov", "url": "https://stacks.cdc.gov/view/cdc/190218/cdc_190218_DS1.pdf", "authors": "stacks.cdc.gov", "host": "stacks.cdc.gov" }, { "number": 20, "title": "Onychomycosis: Old and New - PMC", "detail": "pmc.ncbi.nlm.nih.gov", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC10219498", "authors": "pmc.ncbi.nlm.nih.gov", "host": "pmc.ncbi.nlm.nih.gov" }, { "number": 21, "title": "Onychomycosis: Rapid Evidence Review - PubMed", "detail": "www.ncbi.nlm.nih.gov", "url": "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=34652111", "authors": "www.ncbi.nlm.nih.gov", "host": "www.ncbi.nlm.nih.gov" }, { "number": 22, "title": "Combination Therapy Should Be Reserved as Second-Line Treatment of Onychomycosis: A Systematic Review of Onychomycosis Clinical Trials", "detail": "pmc.ncbi.nlm.nih.gov", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC8949799", "authors": "pmc.ncbi.nlm.nih.gov", "host": "pmc.ncbi.nlm.nih.gov" }, { "number": 23, "title": "Terbinafine - StatPearls - NCBI Bookshelf", "detail": "www.ncbi.nlm.nih.gov", "url": "https://www.ncbi.nlm.nih.gov/books/NBK545218?report=reader", "authors": "www.ncbi.nlm.nih.gov", "host": "www.ncbi.nlm.nih.gov" }, { "number": 24, "title": "Introduction - Clinical Review Report: Efinaconazole (Jublia) - NCBI Bookshelf", "detail": "www.ncbi.nlm.nih.gov", "url": "https://www.ncbi.nlm.nih.gov/books/NBK543985", "authors": "www.ncbi.nlm.nih.gov", "host": "www.ncbi.nlm.nih.gov" } ], "editorialNote": "Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.", "citations": [ { "number": 1, "title": "These highlights do not include all the information needed to use TERBINAFINE TABLETS safely and effectively. See full prescribing information for TERBINAFINE TABLETS.\n \n \n TERBINAFINE tablets, for oral use\n \n \n Initial U.S. Approval: 1992", "detail": "dailymed.nlm.nih.gov", "url": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=34221c17-0d8c-4b56-8af3-c74efab4599e&%3Btype=display", "authors": "dailymed.nlm.nih.gov", "host": "dailymed.nlm.nih.gov", "snippet": "Title: These highlights do not include all the information needed to use TERBINAFINE TABLETS safely and effectively. See full prescribing information for TERBINAFINE TABLETS.\n \n \n TERBINAFINE tablets, for oral use\n \n \n Initial U.S. Approval: 1992\n| | HIGHLIGHTS OF PRES", "score": 0.68090034 }, { "number": 2, "title": "Cost-effectiveness of Confirmatory Testing Before ...", "detail": "jamanetwork.com", "url": "https://jamanetwork.com/journals/DERM/articlepdf/2475012/doi150055.pdf", "authors": "jamanetwork.com", "host": "jamanetwork.com", "snippet": "Dec 23, 2015 — These results show that empirical treatment with terbinafine for patients with suspected onychomycosis is more cost-effective than confirmatory", "score": 0.19006205 }, { "number": 3, "title": "S1 Guideline onychomycosis - Nenoff - 2023 - Wiley Online Library", "detail": "onlinelibrary.wiley.com", "url": "https://onlinelibrary.wiley.com/doi/10.1111/ddg.14988", "authors": "onlinelibrary.wiley.com", "host": "onlinelibrary.wiley.com", "snippet": "10.1111/myc.12925PubMed Web of Science® Google Scholar\n 12Gupta AK, Drummond-Main C, Cooper EA, et al. Systematic review of nondermatophyte mold onychomycosis: diagnosis, clinical types, epidemiology, and treatment. J Am Acad Dermatol. 2012; 66(3): 494-502.\n\n 10.1016/j.jaad.2011.02.038PubMed Web of", "score": 0.68496037 }, { "number": 4, "title": "British Association of Dermatologists' guidelines for the ...", "detail": "onlinelibrary.wiley.com", "url": "https://onlinelibrary.wiley.com/doi/10.1111/bjd.13358", "authors": "onlinelibrary.wiley.com", "host": "onlinelibrary.wiley.com", "snippet": "Onychomycosis is a fungal infection caused by various pathogens, which can adopt any of several clinical patterns. The five main clinical", "score": 0.66621506 }, { "number": 5, "title": "Onychomycosis: a review - Gupta - 2020 - Wiley Online Library", "detail": "onlinelibrary.wiley.com", "url": "https://onlinelibrary.wiley.com/doi/abs/10.1111/jdv.16394", "authors": "onlinelibrary.wiley.com", "host": "onlinelibrary.wiley.com", "snippet": "Onychomycosis is a fungal infection of the nail, causing discoloration and thickening of the affected nail plate, and is the most common nail", "score": 0.444493 }, { "number": 6, "title": "What can GP data tell us about the treatment of onychomycosis in ...", "detail": "onlinelibrary.wiley.com", "url": "https://onlinelibrary.wiley.com/doi/full/10.1002/ski2.84", "authors": "onlinelibrary.wiley.com", "host": "onlinelibrary.wiley.com", "snippet": "Onychomycosis treatment: oral terbinafine being the most commonly used drug in both men and women reflects numerous reports of its higher", "score": 0.35736617 }, { "number": 7, "title": "Comparison of diagnostic methods in the evaluation of onychomycosis - ScienceDirect", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/science/article/pii/S0190962203014804", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com", "snippet": "Title: Comparison of diagnostic methods in the evaluation of onychomycosis - ScienceDirect\nRecent reports have suggested that nail plate biopsy using periodic acid-Schiff (PAS) (Bx/PAS) stain may be a very sensitive technique for the diagnosis of onychomycosis. The purpose of this study was to compa", "score": 0.8302782 }, { "number": 8, "title": "Accuracy of Dermoscopy as a Point-of-Care Tool... : Journal of the Philippine Dermatological Society", "detail": "journals.lww.com", "url": "https://journals.lww.com/jpds/_layouts/15/oaks.journals/downloadpdf.aspx?an=01671546-202511000-00002", "authors": "journals.lww.com", "host": "journals.lww.com", "snippet": "Title: Accuracy of Dermoscopy as a Point-of-Care Tool... : Journal of the Philippine Dermatological Society\n# Accuracy of Dermoscopy as a Point-of-Care Tool for Distal Subungual Onychomycosis at a Tertiary Hospital. The study aimed to evaluate the accuracy of dermoscopy as a point-of-care tool in di", "score": 0.8131201 }, { "number": 9, "title": "Comparative Evaluation of Potassium Hydroxide Mount, Fungal ... : Indian Journal of Dermatopathology and Diagnostic Dermatology", "detail": "journals.lww.com", "url": "https://journals.lww.com/ijdd/fulltext/2021/08010/comparative_evaluation_of_potassium_hydroxide.2.aspx", "authors": "journals.lww.com", "host": "journals.lww.com", "snippet": "Title: Comparative Evaluation of Potassium Hydroxide Mount, Fungal ... : Indian Journal of Dermatopathology and Diagnostic Dermatology\nThis study aims to compare the efficacy of KOH mount, fungal culture, and histopathology of nail clippings with periodic acid–Schiff stain for the diagnosis of onych", "score": 0.78512776 }, { "number": 10, "title": "Onychomycosis: An evaluation of three sampling methods - ScienceDirect", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/science/article/pii/S0190962298702816", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com", "snippet": "Title: Onychomycosis: An evaluation of three sampling methods - ScienceDirect\n## Article preview. ## Journal of the American Academy of Dermatology. Journal of the American Academy of Dermatology. The study included 75 patients with toenail onychomycosis. A single infected toenail was selected and a", "score": 0.78314424 }, { "number": 11, "title": "Dermoscopy of Onychomycosis for the Podiatrist - ScienceDirect", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/science/article/pii/S089184222100046X", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com", "snippet": "Title: Dermoscopy of Onychomycosis for the Podiatrist - ScienceDirect\n## Article preview. # Dermoscopy of Onychomycosis for the Podiatrist. https://doi.org/10.1016/j.cpm.2021.06.006Get rights and content. ## Access through your organization. Check access to the full text by signing in through your o", "score": 0.7065353 }, { "number": 12, "title": "Methods for Diagnosing Onychomycosis: A Comparative Study... : Dermatologica Sinica", "detail": "journals.lww.com", "url": "https://journals.lww.com/ders/fulltext/2019/37020/methods_for_diagnosing_onychomycosis__a.1.aspx", "authors": "journals.lww.com", "host": "journals.lww.com", "snippet": "Title: Methods for Diagnosing Onychomycosis: A Comparative Study... : Dermatologica Sinica\nThere are three common tests used in the outpatient clinic, including direct potassium hydroxide (KOH) examination, nail plate histology study, and fungal culture. The positive rates were significantly differe", "score": 0.6410185 }, { "number": 13, "title": "Diagnosis of onychomycosis made simple - ScienceDirect", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/science/article/abs/pii/S0190962299703919", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com", "snippet": "Elsevier logo\nJournal of the American Academy of Dermatology\n\n## Journal of the American Academy of Dermatology\n\n## Published by: Elsevier\n\n### Published by\n\nElsevier\n\n# Diagnosis of onychomycosis made simple☆,☆☆,★\n\n## Article preview\n\n## Abstract\n\n## Organizational access\n\n### Other access options\n", "score": 0.3538082 }, { "number": 14, "title": "[PDF] Topical Antifungal Prescribing for Medicare Part D Beneficiaries - CDC", "detail": "www.cdc.gov", "url": "https://www.cdc.gov/mmwr/volumes/73/wr/pdfs/mm7301-H.pdf", "authors": "www.cdc.gov", "host": "www.cdc.gov", "snippet": "References 1. Gupta AK, Renaud HJ, Quinlan EM, Shear NH, Piguet V. The growing problem of antifungal resistance in onychomycosis and other superficial mycoses. Am J Clin Dermatol 2021;22:149–57. PMID:33354740 2. Gold JAW, Wu K, Jackson BR, Benedict K. Opportunities to improve guideline adherence fo", "score": 0.46075046 }, { "number": 15, "title": "Traitements topiques et à l'aide de dispositifs pour les ...", "detail": "www.cochranelibrary.com", "url": "https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012093.pub2/references/fr", "authors": "www.cochranelibrary.com", "host": "www.cochranelibrary.com", "snippet": "The effectiveness of lasers in the treatment of onychomycosis: a systematic review. Journal of Foot and Ankle Research 2014;7:34. Link to article · PubMed ...Read more", "score": 0.3813814 }, { "number": 16, "title": "[PDF] List of Publications Using Data from NAMCS and NHAMCS - CDC", "detail": "www.cdc.gov", "url": "https://www.cdc.gov/nchs/media/pdfs/2024/08/namcs_nhamcs_publication_list.pdf", "authors": "www.cdc.gov", "host": "www.cdc.gov", "snippet": "[Epub ahead of print] Roditi RE, Veling M, Shin JJ. Age: An effect modifier of the association between allergic rhinitis and Otitis media with effusion. Laryngoscope. 2015 Sep 30. doi: 10.1002/lary.25682. [Epub ahead of print] Farhangian ME, McMichael AJ, Huang KE, Feldman SR.Treatment of Alopecia A", "score": 0.29234317 }, { "number": 17, "title": "Vital and Health Statistics; Series 11, No. 212 (11/78)", "detail": "www.cdc.gov", "url": "https://www.cdc.gov/nchs/data/series/sr_11/sr11_212.pdf", "authors": "www.cdc.gov", "host": "www.cdc.gov", "snippet": "Nevus. –The Latin for birthmark, is used most commonly for the clinical evidence of aggregates of normal melanocytes or pigment cells in the skin.\nIn color they range from tan, brown to black, in size from millimeters to an entire trunk (giant hairy nevus).\nBy histological level of mektnocytes, they", "score": 0.20793796 }, { "number": 18, "title": "Diagnosing Onychomycosis: What’s New? - PMC", "detail": "www.ncbi.nlm.nih.gov", "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9146047", "authors": "www.ncbi.nlm.nih.gov", "host": "www.ncbi.nlm.nih.gov", "snippet": "Calculations of sensitivity and specificity to assess diagnostic utility depend upon having a reliable reference standard of infection status, but the above limitations provide a significant obstacle to using these methods as reference standards. KOH sensitivity has been calculated from as low as 33", "score": 0.75268626 }, { "number": 19, "title": "[PDF] Confocal Microscopy in Clinical and Surgical Dermatology", "detail": "stacks.cdc.gov", "url": "https://stacks.cdc.gov/view/cdc/190218/cdc_190218_DS1.pdf", "authors": "stacks.cdc.gov", "host": "stacks.cdc.gov", "snippet": "Infections Dermatophyte infections including onychomycosis and tinea pedis are common but may be difficult to diag-nose because potassium hydroxide preparations may be negative and fungal culture is slow. RCM enables rapid real-time identification of branched hyphae and inflammatory infiltrate in vi", "score": 0.4678915 }, { "number": 20, "title": "Onychomycosis: Old and New - PMC", "detail": "pmc.ncbi.nlm.nih.gov", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC10219498", "authors": "pmc.ncbi.nlm.nih.gov", "host": "pmc.ncbi.nlm.nih.gov", "snippet": "Onychomycosis is challenging to treat and is associated with high recurrence rates and treatment failure. Given the limited cure rates with topical antifungals, oral antifungals may be needed in most cases. Oral treatments require lengthy duration of treatment, which poses a risk of adverse effects ", "score": 0.79769903 }, { "number": 21, "title": "Onychomycosis: Rapid Evidence Review - PubMed", "detail": "www.ncbi.nlm.nih.gov", "url": "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=34652111", "authors": "www.ncbi.nlm.nih.gov", "host": "www.ncbi.nlm.nih.gov", "snippet": "Title: Onychomycosis: Rapid Evidence Review - PubMed\nAn official website of the United States government. **The .gov means it’s official.**. Federal government websites often end in .gov or .mil. sharing sensitive information, make sure you’re on a federal. The **https://** ensures that you are conn", "score": 0.76596165 }, { "number": 22, "title": "Combination Therapy Should Be Reserved as Second-Line Treatment of Onychomycosis: A Systematic Review of Onychomycosis Clinical Trials", "detail": "pmc.ncbi.nlm.nih.gov", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC8949799", "authors": "pmc.ncbi.nlm.nih.gov", "host": "pmc.ncbi.nlm.nih.gov", "snippet": "In pivotal RCTs investigating oral terbinafine monotherapy, adverse effects were transient, mild to moderate in severity, and not significantly different from placebo groups . There were no reported laboratory abnormalities . In the terbinafine package insert, liver enzyme abnormalities and taste di", "score": 0.73846215 }, { "number": 23, "title": "Terbinafine - StatPearls - NCBI Bookshelf", "detail": "www.ncbi.nlm.nih.gov", "url": "https://www.ncbi.nlm.nih.gov/books/NBK545218?report=reader", "authors": "www.ncbi.nlm.nih.gov", "host": "www.ncbi.nlm.nih.gov", "snippet": "## Administration\n\nTerbinafine is formulated as a 250 mg tablet to be taken by mouth. The routine dosing for dermatophyte infections is one tablet, by mouth, daily. The duration of therapy varies, with treatment lasting for six weeks for fingernail onychomycosis and up to 12 weeks for toenail onycho", "score": 0.73778254 }, { "number": 24, "title": "Introduction - Clinical Review Report: Efinaconazole (Jublia) - NCBI Bookshelf", "detail": "www.ncbi.nlm.nih.gov", "url": "https://www.ncbi.nlm.nih.gov/books/NBK543985", "authors": "www.ncbi.nlm.nih.gov", "host": "www.ncbi.nlm.nih.gov", "snippet": "agents such as ciclopirox (Table 2).3,13 In general, the duration of treatment with oral agents ranges from 6 to 12 weeks, although treatment of up to six months (terbinafine) or 12 months (fluconazole) may be required.14–16 Treatment with topical ciclopirox typically lasts 48 weeks and also require", "score": 0.734139 } ], "publishedAt": "2026-09-15T23:41:44.423887+00:00", "updatedAt": "2026-09-15T23:41:44.423887+00:00", "readingMinutes": 6, "slug": "onychomycosis" }